Your Trial is at Risk And
You Can’t Afford Non-Adherence!
The High Cost of Poor Adherence
You already know what happens when adherence fails.
Missed doses = compromised endpoints.
Protocol deviations = longer trials, higher costs.
FDA scrutiny = delays, lost funding, and frustrated
The question isn’t whether adherence tracking needs to improve.
The question is: Who will lead the shift toward validated adherence data?
The Industry is Moving— And
Trials MUST Adapt
The FDA is mandating real-world adherence tracking: Trials that rely on self-reporting are at risk of increased scrutiny, loss of funding, and approval delays.
Missed doses = corrupted data = trial failure: Deviations increase costs, cause delays, and put endpoints at risk.
Decentralized trials are becoming the norm: CROs need a passive, automated adherence solution to stay
The trials moving first will establish the industry standard. The ones that wait? They’ll get left behind.
RxKeeper: The First Passive Adherence
Solution Built for Clinical Trials
No Apps, No WiFi, No Behavior Change – Patients simply store their meds inside.
Battery-Operated, Cellular-Connected, Real-Time Adherence Tracking – Adherence data feeds directly into your RPM platform.
Seamless RPM Integration – No additional staff training is required.
Reduces Hospitalizations, Improves Outcomes – Providers retain patients, reduce costs, and improve quality scores.
In Stock & Ready to Deploy – No R&D, no delays—just revenue.
Benefits of ePRO and Medication Adherence in Clinical Trials
Benefits of Patient-Reported Outcomes (ePRO)
Better understanding of patient needs
Ensure better clinical outcomes
​Real-time feedback rather than at scheduled site visits
​Improves participant/protocol compliance
Significantly reduces data collection time
Higher quality data
Accelerates Clinical Trials while Improving Patient Compliance
Benefits of Medication Adherence
Increase efficacy
Helps identify compliance issues early on
Decrease the risk of complications
Decrease the risk of hospitalization
Nonadherence can increase variance, lower study power, and reduce the magnitude of treatment effects.
Increase low patient compliance with prescribed treatments, which is a common problem in clinical trials
How ePRO Works?
The Trials That Move First
Will Lead the Industry
Sponsors are demanding better adherence tracking.
FDA scrutiny is increasing—manual self-reporting won’t be enough.
CROs that deliver validated adherence data will win more sponsor contracts.
The shift is already happening.
Which CROs will own this space—and which will struggle to keep up?